Table 1:
Demographics
| Variable | DSA negative (n=255) |
DSA positive (n=205) |
|---|---|---|
| Female recipient, n (%) | 104 (40.8) | 85 (41.5) |
| Recipient age at first transplant | 59 (16.8) | 55 (22.3) |
| Diagnosis, n (%) | ||
| Interstitial lung disease/pulmonary fibrosis | 115 (45.1) | 87 (42.4) |
| COPD | 65 (25.5) | 44 (21.5) |
| Cystic fibrosis (CF)/non-CF bronchiectasis | 40 (15.7) | 44 (21.5) |
| Pulmonary hypertension | 4 (1.6) | 3 (1.5) |
| Other | 31 (12.2) | 27 (13.2) |
| Lung allocation score at transplant | 40.5 (16) | 42.4 (24) |
| GERD | 113 (44.3) | 77 (37.6) |
| Pre-transplant CPRA | 10.5 (21.3) | 15.2 (24.7) |
| Total HLA mismatch number | 8 (2) | 8 (2) |
| Transplant type, n (%) | ||
| Single | 6 (2.4) | 7 (3.4) |
| Bilateral | 249 (97.6) | 198 (96.6) |
| Intraoperative CPB, yes n (%) | 113 (44.3) | 111 (54.1) |
| Ischemic time, min | 267.5 (97) | 277.5 (110) |
| CMV mismatch (yes), n (%) | 73 (28.9) | 59 (28.9) |
| Allosensitized, n (%) | 91 (35.7) | 72 (35.1) |
| Pre-operative ECMO, n (%) | 2 (0.8) | 2 (1.0) |
| Post-operative ECMO, n (%) | 9 (3.5) | 5 (2.4) |
| Induction immunosuppression | ||
| Basiliximab | 207 (81.2) | 150 (73.2) |
| ATGAM | 43 (16.9) | 44 (21.5) |
| Other | 3 (1.2) | 5 (2.4) |
| None | 1 (0.4) | 3 (1.5) |
| Unknown | 1 (0.4) | 3 (1.5) |
| PGD grade 3 at any time, n (%) | 64 (25.1) | 60 (29.3) |
Abbreviations: COPD: chronic obstructive pulmonary disease; CF: cystic fibrosis; CPRA: calculated panel reactive antibodies; HLA: human leukocyte antigen; CPB: cardiopulmonary bypass; CMV: cytomegalovirus; ECMO: extracorporeal membrane oxygenation; GERD: gastroesophageal reflux disease; ATGAM: antithymocyte globulin; PGD: primary graft dysfunction. Continuous variables are represented as median (interquartile range) except for cPRA, which is represented as mean (standard deviation) as the median was 0 in both groups.